InsidersTradesSigma
Total declarations
Companies
▲ Purchases (2 ops.)
▼ Sales (1 ops.)
Discover the full record of transactions filed by Chin Mark, Directeur. Director active across 3 companies, notably IMARA Inc.. Aggregated, 7 filings have been recorded. Total volume traded: €18.5m. The latest transaction was disclosed on 21 April 2022 — Cession. Regulator: SEC (Form 4). The full history is free.
Declarations7 total
36,798 shares
Ordinary Shares
SEC:0001209191-22-039313:0·
€5m1,745,761 shares@ €2.81493.40% mcap100.0% of flow
Common Stock
SEC:0000899243-22-015542:0·
066,831 shares0
Common Stock
SEC:0001140361-22-012917:0·
1,433,261 shares
Common Stock
SEC:0001140361-21-034645·
1,433,261 shares
Common Stock
SEC:0001140361-21-034645:0·
€7m1,333,333 shares@ €5.0797100.0% of flow
Common Stock
SEC:0001209191-21-048395·
Ideal exit: 12 Apr 2022 (T+270)
€7m1,333,333 shares@ €5.079750.0% of flow
Common Stock
SEC:0001209191-21-048395:0·
Ideal exit: 12 Apr 2022 (T+270)
7 of 7 declarations
About Chin Mark
Mark Chin is a Director at Imara Inc., Pyxis Oncology, Inc., and Iterum Therapeutics plc. He is involved in overseeing activities and strategic decision-making for these companies. His experience in the pharmaceutical sector contributes to the direction and growth of the organizations. As a board member, he ensures governance and compliance of practices.
